CD38 and Miyoshi myopathy: Although Mab-CD38 was associated with impaired serological responses (40–60%) in MM patients in several studies [18, 20, 45, 168], many studies showed approximately 90% seroconversion rates in MM patients treated with Mab-CD38 [27, 58, 100, 109, 154].